scholarly journals Inhibitory role of Metformin for tamoxifen induced ‎uterine cell proliferation in diabetic ‎patients with ER-‎positive Breast cancer

2019 ◽  
Vol 10 (3) ◽  
pp. 2538-2541 ◽  
Author(s):  
Ghasak Kais Abd-Alhussain ◽  
Mohammed Qasim Yahya Mal-Allah Al-Atrakji ◽  
Wieeam Abdulfattah Saleh ◽  
Aqeel Shaker Mahmood
Keyword(s):  
Breast Cancer ◽  
Diabetic Patient ◽  
Diabetic Patients ◽  
Hypoglycemic Agent ◽  
Er Positive ◽  
Group A ◽  
Group B ◽  
Uterine Polyps ◽  
Positive Breast Cancer

The objective of the current work to evaluate the role of metformin in inhibiting the tamoxifen induced ‎endometrial ‎changes in diabetic patients with ER-positive breast cancer, a case-control study, carried out between December 2018 to May 2019, forty ‎diabetic women in postmenopausal phase with ER+ breast cancer on tamoxifen (20mg/day), ‎metformin ‎‎(1700 mg/day) GROUP A, and 40 diabetic patients with ER+ breast cancer on the ‎same dose of tamoxifen, but other hypoglycemic agent GROUP B, were selected as controls. ‎Uterine thickness was assessed by ultrasonography imaging at the beginning of treatment with ‎tamoxifen and after 2 years of treatment. Hysteroscopy ‎was done, and pathological findings also ‎recorded.‎ Mean uterine thickness of diabetic patients on other hypoglycemic was ‎significantly higher than diabetic patients on metformin (14.79±3.6 vs 4.37±1.8). Uterine ‎thickness >5mm were 2 (5%) vs ‎36 (85%) reported with the diabetic patient on metformin and the ‎diabetic patient on ‎other oral hypoglycemic group. Three cases (7.5%) of the diabetic patients ‎on other hypoglycemic agent were developed uterine polyps, and one case (2.5%) of diabetic ‎patients on metformin were developed uterine polyps. One case (2.5%) of uterine carcinoma ‎was reported with diabetic patients on other hypoglycemic group.‎ In conclusions metformin significantly inhibit tamoxifen-induced endometrial changes and ‎offers favorable endometrium protection.

Abstract 552: The role of the mTORC1/S6K1 signaling pathway in ER-positive breast cancer.

2013 ◽  
Author(s):  
Anya Sedletcaia ◽  
Helen A. Unger ◽  
Rose B. Snyder ◽  
Marina K. Holz
Keyword(s):  
Breast Cancer ◽  
Signaling Pathway ◽  
Er Positive ◽  
Positive Breast Cancer

Should liver metastases of breast cancer be biopsied to improve treatment choice?

2010 ◽  
Vol 28 (18_suppl) ◽  
pp. CRA1008-CRA1008 ◽  
Author(s):  
M. A. Locatelli ◽  
G. Curigliano ◽  
L. Fumagalli ◽  
V. Bagnardi ◽  
G. Aurilio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Primary Tumor ◽  
Treatment Choice ◽  
Her2 Status ◽  
Her2 Positive ◽  
Tissue Samples ◽  
Er Positive ◽  
Group A ◽  
Group B

CRA1008 Background: Decision making on systemic treatment of women with metastatic breast cancer is based on features like estrogen receptor (ER), progesterone receptor (PgR), and HER2 status assessed on the primary tumor. We evaluated the concordance of receptor status between primary tumor and liver metastases (mts) and its impact on treatment choice. Methods: We retrospectively analyzed a database including ultrasound guided liver biopsies performed from 1995 to 2008. All tissue samples, both from primary tumor and liver mts, were analyzed for ER, PgR and HER2 status. Clinical and biological data were obtained from medical charts. Differences between proportions were evaluated using the Pearson chi-square test. Results: We identified 255 consecutive patients (pts) with matched primary and liver tissue samples. Median time from primary diagnosis to liver biopsy was 3.4 years (range 0-18.3 years). Changes in ER status were observed in 41/255 pts (16.0%). 16/58 pts (27.6%) changed from ER-negative to ER-positive and 25/197 pts (12.7%) changed from ER-positive to ER-negative (p=0.0066). Changes in PgR status were observed in 76/255 pts (29.8%). 18/91 pts (19.8%) changed from PgR-negative to -positive and 58/164 pts (64.6%) from PgR-positive to PgR-negative (p <0.0001). 12/52 pts (23.1%) changed from ER- and PgR-negative to ER- or PgR-positive (group A) and 27/203 pts (13.3%) changed from ER- or PgR-positive to ER- and PgR-negative (group B) (p=0.087). In the group A the treatment of 4/12 pts (33.3%) was changed after biopsy: 2/4 started endocrine treatment (HT) and 2/4 stopped it. In group B the treatment of 18/27 pts (66.6%) was changed after biopsy: 17/18 stopped HT. Changes in HER2 status were observed in 22/167 pts (13.1%): 6/116 pts (5.1%) changed from HER2-negative to HER2-positive and 16/51 pts (31.4%) changed from HER2-positive to negative (p≤0.0001). In this group pts started and/or stopped a trastuzumab containing treatment after biopsy. Conclusions: There was a discordance in receptor status between primary tumor and liver mts, which led to change in therapy for 48/255 of pts (18.8%). Biopsy of metastases for reassessment of biological features should be considered in all pts when safe and easy to perform, since it is likely to impact treatment choice. No significant financial relationships to disclose.

scholarly journals Androgen Receptor Expression Associates With Distinctive Clinicopathological and Molecular Features in ER-Positive and ER-Negative Breast Cancer

2021 ◽  
Author(s):  
Taobo Hu ◽  
Yiqiang Liu ◽  
Guiyang Zhao ◽  
Shu Wang ◽  
Mengping Long
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Clinicopathological Characteristics ◽  
Receptor Expression ◽  
Molecular Features ◽  
Molecular Correlation ◽  
Er Positive ◽  
Er Expression ◽  
Positive Breast Cancer

Abstract Background: Androgen receptor (AR) expression is frequently observed in breast cancer, but its association with estrogen receptor (ER) expression of breast cancer remains unclear. Methods: In this study, we analyzed the clinicopathological and molecular features associated AR loss in ER-positive and ER-negative breast cancer respectively, trying to elucidate the molecular correlation between AR and ER. Results: Our results showed that AR loss was associated with different clinicopathological characteristics in ER-positive and ER-negative breast cancer. Moreover, the expression of AR was correlated with different molecular features in ER-positive and ER-negative breast cancer.Conclusions: These results suggest that the role of AR in ER-positive breast cancer is distinctive from that in ER-negative breast cancer.

scholarly journals Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4

BMC Cancer ◽  
2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Aamir Ahmad ◽  
Kevin R. Ginnebaugh ◽  
Shuping Yin ◽  
Aliccia Bollig-Fischer ◽  
Kaladhar B. Reddy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Functional Role ◽  
Breast Cancer Cells ◽  
Tamoxifen Resistance ◽  
Down Regulation ◽  
Er Positive ◽  
Positive Breast Cancer

scholarly journals Hyperglycemic Response of Non-diabetic Women Undergoing Abdominal Hysterectomy Who Have Received Prophylactic Dexamethasone to Alleviate Nausea and Vomiting

2020 ◽  
Author(s):  
Saghar Samimi Sadeh ◽  
Ehsan Bastanhagh ◽  
Somayeh Mohammadi ◽  
Reza Shariat Moharari ◽  
Pejman Pourfakhr ◽  
...  
Keyword(s):  
Normal Saline ◽  
Abdominal Hysterectomy ◽  
Nausea And Vomiting ◽  
Diabetic Patients ◽  
Anesthetic Induction ◽  
Double Blind ◽  
Group A ◽  
Group B ◽  
Post Operative Nausea

Background: This study has been designed to assess the hyperglycemic response in non-diabetic patients in women undergoing abdominal hysterectomy; who have received a prophylactic dose of dexamethasone to alleviate post-operative nausea and vomiting (PONV). Methods: This was a double blind randomized clinical trial involving seventy women who were candidates for abdominal hysterectomy. The women were randomly assigned into two groups. Group A received 8mgs (in 50 mls normal saline) of IV dexamethasone; post-anesthetic induction and pre-surgery. Group B received 50 mls of normal saline post-anesthetic induction and pre-surgery. Patients were asked whether they had any nausea and vomiting during recovery. The patients’ blood sugar (BS) levels were assessed before surgery, during recovery and then 1, 6, 12, 18, and 24 hours after surgery. Results: Thirty-three women in each group were monitored. Assessment of the results indicates that nausea and vomiting were not significantly different between the two groups. The age and BS before surgery of the patients were not significantly different. BS levels after surgery were significantly higher for the group receiving dexamethasone; with the exception of the levels during the first hour. Conclusion: The BS of women undergoing abdominal hysterectomy is significantly higher for those receiving a single dose of dexamethasone, post-operatively, compared to patients receiving a placebo. The finding of this study does not support the role of dexamethasone in the prophylactic anti-emetic treatment in abdominal hysterectomy.

scholarly journals Androgen Receptor Expression Associates With Distinctive Clinicopathological and Molecular Features in ER-Positive and ER-Negative Breast Cancer

2021 ◽  
Author(s):  
Taobo Hu ◽  
Yiqiang Liu ◽  
Guiyang Zhao ◽  
Shu Wang ◽  
Mengping Long
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Clinicopathological Characteristics ◽  
Receptor Expression ◽  
Molecular Features ◽  
Molecular Correlation ◽  
Er Positive ◽  
Er Expression ◽  
Positive Breast Cancer

Abstract Background Androgen receptor (AR) expression is frequently observed in breast cancer, but its association with estrogen receptor (ER) expression of breast cancer remains unclear. Methods In this study, we analyzed the clinicopathological and molecular features associated AR loss in ER-positive and ER-negative breast cancer respectively, trying to elucidate the molecular correlation between AR and ER. Results Our results showed that AR loss was associated with different clinicopathological characteristics in ER-positive and ER-negative breast cancer. Moreover, the expression of AR was correlated with different molecular features in ER-positive and ER-negative breast cancer. Conclusions These results suggest that the role of AR in ER-positive breast cancer is distinctive from that in ER-negative breast cancer.

scholarly journals Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer

2015 ◽  
Vol 75 (2) ◽  
pp. 405-414 ◽  
Author(s):  
Neil E. Bhola ◽  
Valerie M. Jansen ◽  
Sangeeta Bafna ◽  
Jennifer M. Giltnane ◽  
Justin M. Balko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Functional Screen ◽  
Er Positive ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document